Abstract
33 families with a history of male breast cancer aged 60 or less or with a family history of male and female breast cancer were screened for the presence of BRCA2 mutations. 12 pathogenic BRCA2 mutations were identified (36%) in samples from an affected family member. All mutations segregated with disease where it was possible to check. Of the 14 families fulfilling BCLC criteria, 9 (64%) had mutations whilst only 3/16 (19%) of male breast cancer patients with less significant female breast cancer family history having a mutation. All 3 families with ovarian cancer and 3 families with multiple male breast cancer cases had BRCA2 mutations. These data are a further guide to how to prioritise samples for BRCA2 mutation analysis.
Similar content being viewed by others
References
Couch FJ, Farid LM, Deshano ML et al. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nature Genet 1996; 13: 123-5.
Thorlacius S, Olafsdottir G, Trygvaddottir L et al. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nature Genet 1996; 13: 117-9.
Friedman LS, Gayther SA, Kurosaki T et al. Mutation anlysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet 1997; 60: 313-9.
Mavraki E, Gray IC, Bisop DT et al. Germline BRCA2 mutations in men with breast cancer. Br J Cancer 1997; 76: 1428-31.
Haraldsson K, Loman N, Zhang QX et al. BRCA2 germline mutations are frequent in male breast cancer patients without a family history of the disease. Cancer Res 1998; 58: 1367-71.
Csokay B, Udvarhelyi N, Sulyok Z et al. High frequency of germline BRCA2 mutations among Hungarian male breast cancer patients without family history. Cancer Res 1999; 59: 995-8.
Basham VM, Lipscombe JM, Ward JM et al. BRCA1 and BRCA2 mutations in a population based study of male breast cancer. Breast Cancer Res 2001; 4: 1-5.
Ford D, Easton M, Stratton S et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998; 62: 676-89.
Davies JF, Redmond EK, Cox MC et al. 2157 del G: a frequent mutation in BRCA2 missed by PTT. J Med Genet 2000; 37: e42.
Eng C, Brady LC, Wagner TMU et al. Interpreting epidemiological research: blinded comparison of methods used to etimate prevalence of inherited mutations in BRCA1. J Med Genet 2001; 38: 824-33.
Gayther SA, Mangion J, Russell P. Variations of risks of breast and ovarian cancer associated with different germ-line mutations of the BRCA2 gene. Nature Genet 1997; 15: 103-5.
Thompson D Easton D. Variation in cancer risks, by mutation position in BRCA2 carriers. Am J Hum Genet 2001; 68: 410-9.
Breast Cancer Information Core: http://www.nhgri.nih.gov/ Intramural_research/Lab_transfer/Bic/
Wooster R, Bignell G, Lancaster J et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789-92.
Meijers-Heijboer H, van den Ouweland A, Klijn J et al. Low penetrance breast cancer susceptibility due to CHK2 1100delC in non-carriers of BRCA1 or BRCA2 mutations. Nature Genet 2002; 31: 55-9.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Evans, D.G.R., Bulman, M., Young, K. et al. High detection rate for BRCA2 mutations in male breast cancer families from North West England. Familial Cancer 1, 131–133 (2001). https://doi.org/10.1023/A:1021165031643
Issue Date:
DOI: https://doi.org/10.1023/A:1021165031643